NEW YORK — Canadian consumer health firm PanGenomic Health said last week that its MUJN Diagnostics subsidiary has partnered with Hemex Health to develop point-of-care diagnostics for use with alternative brain health therapies.
Under the terms of their master services agreement, MUJN will develop biomarker panels that track a patient's response to alternative brain and mental health treatments such as psychedelics. Portland, Oregon-based Hemex will adapt its portable, point-of-care Gazelle instrument to run the cartridge-based tests.
PanGenomic said that MUJN and Hemex have already initiated the diagnostic cartridge design phase of the alliance. Financial and other terms of the deal were not disclosed.
In mid-2021, Hemex struck an alliance to offer Mylab Discovery Solutions' assays for COVID-19 and other diseases on the Gazelle system.